P3 Health Partners Inc. reports developments in population health management, value-based primary care and physician-led care coordination. The company supports community providers through administrative services, clinical operations, data-driven care enablement and partnerships tied to Medicare Advantage, accountable care organizations and delegated-risk arrangements.
Recurring updates include quarterly results, guidance, revenue trends, capitated revenue per member, medical margin, adjusted EBITDA and operating changes in the Care Enablement Model. Company news also covers payer and provider agreements, ACO management services, market expansion, investor conference participation and joint venture activity such as the P3 Commonwealth Innovation MSO.
P3 Health Partners Inc. (NASDAQ: PIII) invites investors to a fireside chat on August 31, 2022, at 2 pm ET. CEO Dr. Sherif Abdou and CMO Dr. Amir Bacchus will discuss the company's operations and value-based care model aimed at reducing healthcare delivery costs. The session will also highlight P3's achievements in 2022, emphasizing their commitment to improving patient outcomes through a network of over 2,500 primary care providers across five states.
P3 Health Partners Inc. (NASDAQ: PIII) has reached an agreement with Humana, allowing Humana Medicare Advantage members access to P3's primary care network in Clark and Nye Counties. From January 1, 2023, members will be able to visit P3's 10 clinics and over 400 PCPs. The initiative aims to enhance healthcare accessibility for Medicare beneficiaries in Southern Nevada. The announcement coincides with the Medicare Annual Election Period, beginning October 15, 2022, where members can select Humana plans pending regulatory approval.
P3 Health Partners Inc. (NASDAQ: PIII) announced an interview with its founder and CEO Dr. Sherif Abdou on the Benchtop Bios podcast. Dr. Abdou discusses P3's innovative value-based healthcare model aimed at enhancing patient care for Medicare Advantage patients. The podcast, featuring industry leaders, aims to inform biotech and healthcare investors about significant trends and discoveries shaping modern healthcare. P3, with over 2,500 affiliated primary care providers, focuses on improving patient outcomes and lowering costs through coordinated care.
Summary not available.
P3 Health Partners Oregon has announced a multi-year partnership with Oregon State University Athletics, enhancing its visibility among senior fans. Starting in the 2022-23 season, P3 will introduce the first-ever Oregon State University Senior Cheer Squad. This initiative will include performances during women’s basketball games and coverage in digital programs. P3 will also sponsor game broadcasts, starting lineups for home basketball matches, and special events like Grandparents Day. This collaboration aims to strengthen community ties and engage senior patients who have connections with the university.
P3 Health Partners (NASDAQ: PIII) has been added to the Russell 3000 Index, effective June 27, 2022, marking a significant milestone for the company. This inclusion enhances visibility and liquidity for shareholders and confirms the company’s position among the top 4,000 U.S. stocks based on market capitalization. FTSE Russell, which manages the Russell indexes, oversees approximately $12 trillion in assets benchmarked against these indexes, further solidifying P3's market presence as it continues to work towards its strategic vision of transforming healthcare.
Summary not available.
P3 Health Partners, Inc. (NASDAQ: PIII) will release its financial results for Q4 and full year 2021 on April 25, 2022, after market close. A conference call and webcast for investors will be held the same day at 4:30 PM ET. The company anticipates reporting revenue and adjusted EBITDA aligning with preliminary results shared on March 9, 2022. P3 has filed for a 15-day extension for its Form 10-K due to incomplete disclosures, but reports no disagreements with its auditors.
P3 Health Partners reported a strong revenue growth of 46% for Q4 2021 and 32% for the full year, projecting 2022 revenue up to $1 billion (a 56% increase). The company aims for 95,000 at-risk Medicare Advantage members by year-end, a 42% rise. Adjusted EBITDA is expected to improve significantly, with profitability anticipated by 2024. Despite a net loss of up to $95 million for Q4, a robust cash position of $140 million at year-end supports operations. P3 will file for a late 10-K extension, expecting to release detailed results by April 15, 2022.
P3 Health Partners, Inc. (NASDAQ: PIII), a physician-led population health management company, announced its participation in three investor conferences in March 2022. The company will present at the Cowen 42nd Annual Healthcare Conference on March 9, attend the 34th Annual ROTH Conference on March 14 in Dana Point, CA, and participate in the Barclays Global Healthcare Conference on March 16 in Miami, FL. Live webcasts will be available on P3’s investor relations website, providing access to presentations and replays.